Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-cancer Therapeutic Compounds

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Mar 5

PMID 21373641

Citations 14

Authors

Caterina Cinti

Monia Taranta

Ilaria Naldi

Settimio Grimaldi

Affiliations

Soon will be listed here.

Abstract

Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy.

Citing Articles

Erythro-Magneto-HA-Virosome: A Bio-Inspired Drug Delivery System for Active Targeting of Drugs in the Lungs.

Vizzoca A, Lucarini G, Tognoni E, Tognarelli S, Ricotti L, Gherardini L Int J Mol Sci. 2022; 23(17).

PMID: 36077300 PMC: 9455992. DOI: 10.3390/ijms23179893.

Red Blood Cell Inspired Strategies for Drug Delivery: Emerging Concepts and New Advances.

Zhang E, Phan P, Algarni H, Zhao Z Pharm Res. 2022; 39(11):2673-2698.

PMID: 35794397 DOI: 10.1007/s11095-022-03328-5.

Silencing Survivin: a Key Therapeutic Strategy for Cardiac Hypertrophy.

Kusmic C, Vizzoca A, Taranta M, Tedeschi L, Gherardini L, Pelosi G J Cardiovasc Transl Res. 2021; 15(2):391-407.

PMID: 34409583 DOI: 10.1007/s12265-021-10165-1.

Epigenetics in cancer therapy and nanomedicine.

Roberti A, Valdes A, Torrecillas R, Fraga M, Fernandez A Clin Epigenetics. 2019; 11(1):81.

PMID: 31097014 PMC: 6524244. DOI: 10.1186/s13148-019-0675-4.

Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.

Ye H, Tong J, Liu J, Lin W, Zhang C, Chen K Oncotarget. 2016; 7(28):43762-43778.

PMID: 27248325 PMC: 5190058. DOI: 10.18632/oncotarget.9671.

References

Wallace S . Biological consequences of free radical-damaged DNA bases. Free Radic Biol Med. 2002; 33(1):1-14. DOI: 10.1016/s0891-5849(02)00827-4. View

Price R, Skyba D, Kaul S, Skalak T . Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation. 1998; 98(13):1264-7. DOI: 10.1161/01.cir.98.13.1264. View

Leone G, Teofili L, Voso M, Lubbert M . DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002; 87(12):1324-41. View

Orekhova N, Akchurin R, Belyaev A, Smirnov M, Ragimov S, Orekhov A . Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. Thromb Res. 1990; 57(4):611-6. DOI: 10.1016/0049-3848(90)90078-q. View

Gorantla S, Dou H, Boska M, Destache C, Nelson J, Poluektova L . Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol. 2006; 80(5):1165-74. DOI: 10.1189/jlb.0206110. View

Agnihotri S, Mallikarjuna N, Aminabhavi T . Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004; 100(1):5-28. DOI: 10.1016/j.jconrel.2004.08.010. View

Soppimath K, Aminabhavi T, Kulkarni A, Rudzinski W . Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001; 70(1-2):1-20. DOI: 10.1016/s0168-3659(00)00339-4. View

Appleton K, MacKay H, Judson I, Plumb J, McCormick C, Strathdee G . Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007; 25(29):4603-9. DOI: 10.1200/JCO.2007.10.8688. View

Patel K, Guichard S, Jodrell D . Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 863(1):19-25. DOI: 10.1016/j.jchromb.2007.12.014. View

10.

Moghimi S, Hunter A . Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst. 2002; 18(6):527-50. View

11.

Rossi L, Serafini S, Pierige F, Antonelli A, Cerasi A, Fraternale A . Erythrocyte-based drug delivery. Expert Opin Drug Deliv. 2005; 2(2):311-22. DOI: 10.1517/17425247.2.2.311. View

12.

Mayer C, Geis N, Katus H, Bekeredjian R . Ultrasound targeted microbubble destruction for drug and gene delivery. Expert Opin Drug Deliv. 2008; 5(10):1121-38. DOI: 10.1517/17425247.5.10.1121. View

13.

Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S . Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release. 2007; 118(2):145-60. DOI: 10.1016/j.jconrel.2006.06.032. View

14.

Juttermann R, Li E, Jaenisch R . Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994; 91(25):11797-801. PMC: 45322. DOI: 10.1073/pnas.91.25.11797. View

15.

Magnani M, Rossi L, Fraternale A, Bianchi M, Antonelli A, Crinelli R . Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther. 2002; 9(11):749-51. DOI: 10.1038/sj.gt.3301758. View

16.

Kumar M, Bakowsky U, Lehr C . Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004; 25(10):1771-7. DOI: 10.1016/j.biomaterials.2003.08.069. View

17.

Mundargi R, Babu V, Rangaswamy V, Patel P, Aminabhavi T . Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2007; 125(3):193-209. DOI: 10.1016/j.jconrel.2007.09.013. View

18.

Liu M, Kono K, Frechet J . Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release. 2000; 65(1-2):121-31. DOI: 10.1016/s0168-3659(99)00245-x. View

19.

Bittner B, Ronneberger B, Zange R, Volland C, Anderson J, Kissel T . Bovine serum albumin loaded poly(lactide-co-glycolide) microspheres: the influence of polymer purity on particle characteristics. J Microencapsul. 1998; 15(4):495-514. DOI: 10.3109/02652049809006876. View

20.

Hamidi M, Tajerzadeh H . Carrier erythrocytes: an overview. Drug Deliv. 2003; 10(1):9-20. DOI: 10.1080/713840329. View